These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38316960)

  • 21. Antibiotics for secondary prevention of coronary heart disease.
    Sethi NJ; Safi S; Korang SK; Hróbjartsson A; Skoog M; Gluud C; Jakobsen JC
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD003610. PubMed ID: 33704780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hospitalisation and mortality in patients with comorbid COPD and heart failure: a systematic review and meta-analysis.
    Axson EL; Ragutheeswaran K; Sundaram V; Bloom CI; Bottle A; Cowie MR; Quint JK
    Respir Res; 2020 Feb; 21(1):54. PubMed ID: 32059680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The obesity paradox: body mass index and outcomes in patients with heart failure.
    Curtis JP; Selter JG; Wang Y; Rathore SS; Jovin IS; Jadbabaie F; Kosiborod M; Portnay EL; Sokol SI; Bader F; Krumholz HM
    Arch Intern Med; 2005 Jan; 165(1):55-61. PubMed ID: 15642875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between prediabetes and adverse outcomes in heart failure.
    Mai L; Wen W; Qiu M; Liu X; Sun L; Zheng H; Cai X; Huang Y
    Diabetes Obes Metab; 2021 Nov; 23(11):2476-2483. PubMed ID: 34227220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subclinical thyroid dysfunction is associated with adverse prognosis in heart failure patients with reduced ejection fraction.
    Yang G; Wang Y; Ma A; Wang T
    BMC Cardiovasc Disord; 2019 Apr; 19(1):83. PubMed ID: 30947691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association Between Disease-specific Health-related Quality of Life and All-cause Mortality in Patients with Heart Failure: A Meta-analysis.
    Xu J; Sun Y; Gong D; Fan Y
    Curr Probl Cardiol; 2023 Apr; 48(4):101592. PubMed ID: 36632931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjusting for reverse causation to estimate the effect of obesity on mortality after incident heart failure in the Atherosclerosis Risk in Communities (ARIC) study.
    Shakiba M; Soori H; Mansournia MA; Nazari SSH; Salimi Y
    Epidemiol Health; 2016; 38():e2016025. PubMed ID: 27283142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Community-based care for the specialized management of heart failure: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(17):1-42. PubMed ID: 23074521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cystatin C for predicting all-cause mortality and rehospitalization in patients with heart failure: a meta-analysis.
    Chen S; Tang Y; Zhou X
    Biosci Rep; 2019 Feb; 39(2):. PubMed ID: 30643006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. No benefit from the obesity paradox for diabetic patients with heart failure.
    Zamora E; Lupón J; Enjuanes C; Pascual-Figal D; de Antonio M; Domingo M; Comín-Colet J; Vila J; Peñafiel J; Farré N; Alonso N; Santesmases J; Troya M; Bayés-Genís A
    Eur J Heart Fail; 2016 Jul; 18(7):851-8. PubMed ID: 27312985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis.
    Cardoso R; Graffunder FP; Ternes CMP; Fernandes A; Rocha AV; Fernandes G; Bhatt DL
    EClinicalMedicine; 2021 Jun; 36():100933. PubMed ID: 34308311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of weight loss on clinical outcomes in patients implanted with a cardiac resynchronization therapy device-A MADIT-CRT substudy.
    Aktas MK; Zareba W; Huang DT; McNitt S; Polonsky S; Chen L; Stockburger M; Merkely B; Moss AJ; Kutyifa V
    J Card Fail; 2014 Mar; 20(3):183-9. PubMed ID: 24361804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of weight loss medications on mortality and cardiovascular events: A systematic review of randomized controlled trials in adults with overweight and obesity.
    Capristo E; Maione A; Lucisano G; Russo MF; Mingrone G; Nicolucci A
    Nutr Metab Cardiovasc Dis; 2021 Aug; 31(9):2587-2595. PubMed ID: 34154892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis.
    Banerjee M; Maisnam I; Pal R; Mukhopadhyay S
    Eur Heart J; 2023 Oct; 44(37):3686-3696. PubMed ID: 37605637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of weight loss in patients with heart failure with preserved ejection fraction: results from the FLAGSHIP study.
    Kamisaka K; Kamiya K; Iwatsu K; Iritani N; Imoto S; Adachi T; Iida Y; Yamada S;
    ESC Heart Fail; 2021 Dec; 8(6):5293-5303. PubMed ID: 34599855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS.
    Domanski MJ; Krause-Steinrauf H; Massie BM; Deedwania P; Follmann D; Kovar D; Murray D; Oren R; Rosenberg Y; Young J; Zile M; Eichhorn E;
    J Card Fail; 2003 Oct; 9(5):354-63. PubMed ID: 14583895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
    Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure.
    Marso SP; Baeres FMM; Bain SC; Goldman B; Husain M; Nauck MA; Poulter NR; Pratley RE; Thomsen AB; Buse JB;
    J Am Coll Cardiol; 2020 Mar; 75(10):1128-1141. PubMed ID: 32164886
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.